Ranee Mehra - Concepedia

Author

Ranee Mehra

Also Known As

Mehra R, Mehra,Ranee, Moore, Dominic T., Patel, Shetal, R K Mehra, R Mehra, R. Mehra, Ranee Mehra, Rubin S Mehra, Tahara, Makoto

399

Publications

16K

Citations

H-Index

116

Concepts

All Affiliations

Fox Chase Cancer Center Johns Hopkins University Yale Cancer Center University of Maryland, Baltimore University of Washington

About

Ranee Mehra is an author at Fox Chase Cancer Center specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	55	8.5K
2	Health Sciences	14	18	1.1K
3	Cell Biology	4	4	60
4	Public Health	2	2	20
5	Allergy	1	1	11

Ranee Mehra

102

Publications

12.8K

Citations

H-Index

Page 1

	Year	Citations
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial Tanguy Y. Seiwert, Barbara Burtness, Ranee Mehra, The Lancet Oncology Phase 1BMedicinePathologyHead And Neck CancerCancer Treatment	2016	1.7K
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau, The Lancet MedicinePathologyHead And Neck CancerCancer TreatmentNeck Oncology	2018	1.6K
Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer Alice T. Shaw, Dong-Wan Kim, Ranee Mehra, New England Journal of Medicine	2014	1.4K
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort Laura Q.M. Chow, Robert I. Haddad, Shilpa Gupta, Journal of Clinical Oncology Antitumor ActivityImmunologyPathologyPharmacotherapyImmunotherapy	2016	846
Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer Ezra E.W. Cohen, Theodore Karrison, Masha Kocherginsky, Journal of Clinical Oncology	2014	558
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer Razelle Kurzrock, Steven I. Sherman, Douglas W. Ball, Journal of Clinical Oncology	2011	546
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial Dong‐Wan Kim, Ranee Mehra, Daniel S.W. Tan, The Lancet Oncology MedicinePathologyImmune Checkpoint InhibitorCancer TreatmentOncology	2016	467
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 Ranee Mehra, Tanguy Y. Seiwert, Shilpa Gupta, British Journal of Cancer	2018	443
Survival Impact of Increasing Time to Treatment Initiation for Patients With Head and Neck Cancer in the United States Colin T. Murphy, Thomas J. Galloway, Elizabeth A. Handorf, Journal of Clinical Oncology	2015	414
Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy Rajani Ravi, Kimberly Noonan, Vui Pham, Nature Communications	2018	323

Page 1